[Form 4] Editas Medicine, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Editas Medicine insider sale disclosed on Form 4: Amy Parison, SVP and Chief Financial Officer, reported a transaction dated 09/03/2025 showing the disposition of 458 shares of Editas Medicine common stock at a price of $2.5961 per share. After the sale, Ms. Parison beneficially owned 16,369 shares, held directly. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 7, 2022, to satisfy tax withholding obligations tied to the vesting of restricted stock units on 09/02/2025, and that the sale was not a discretionary trade by the reporting person.

Insights

Financial Analyst

TL;DR: Small, non-discretionary insider sale for tax withholding; not likely material to company valuation.

The transaction involves 458 shares sold at $2.5961 to cover tax withholding from RSU vesting, leaving the CFO with 16,369 shares. Because the sale was executed pursuant to a pre-existing automatic plan (10b5-1 style) and is explicitly for tax withholding, it reduces the likelihood that this reflects a deliberate view on company prospects. The absolute size of the sale appears modest relative to typical market volumes and outstanding shares, so investor impact should be limited.

Corporate Governance Expert

TL;DR: Governance signal: use of an automatic plan meets affirmative defense conditions and documents non-discretionary intent.

The filing documents that the sale was made under a durable automatic sales instruction plan adopted July 7, 2022, which supports compliance with Rule 10b5-1 affirmative defense standards. The explicit statement that the sale solely satisfied tax withholding for RSU vesting and was not discretionary strengthens the governance transparency of the reporting officer. No other governance issues or amendments are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parison Amy

(Last) (First) (Middle)

11 HURLEY STREET

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S(1)		458	D	$2.5961	16,369	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Amy Parison	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Editas Medicine CFO Amy Parison sell on 09/03/2025?

The CFO sold 458 shares of Editas Medicine common stock at $2.5961 per share on 09/03/2025.

Why were the shares sold by Amy Parison according to the Form 4?

The sale was made under a durable automatic sales instruction plan to satisfy tax withholding obligations arising from RSU vesting on 09/02/2025.

How many Editas Medicine shares does Amy Parison own after the reported transaction?

After the reported sale, the filing shows she beneficially owns 16,369 shares (direct ownership).

Was the sale a discretionary trade by the reporting person?

No. The Form 4 states the sale does not represent a discretionary trade and was effected pursuant to an automatic plan adopted on 07/07/2022.

Does the Form 4 indicate any other transactions or amendments?

No. The filing reports only the single non-derivative sale of 458 shares and a signature dated 09/04/2025 by Amy Parison.